Announcement: New Director of the Division of Global HIV/AIDS letter

Posted on in Breaking News, HIV/AIDS, News Center

Letter sent on behalf of Dr. Tom Kenyon, Director, Center for Global Health, CDC:

It is my pleasure to welcome back Dr. Shannon Hader to CDC. Starting October 6th, Dr. Hader will serve as the new Director of the Division of Global HIV/AIDS (DGHA) in the Center for Global Health. Dr. Hader brings to CDC an extensive background in domestic and international HIV/AIDS. Specifically, she has worked in challenging socio-economic and political environments from rural Mississippi to rural Russia, and has emphasized accountability, scale and impact for sustainable responses from Washington, D.C. to Zimbabwe.

Dr. Hader began her career at CDC in 1999 as an epidemic intelligence service officer in the Division of HIV/AIDS Prevention. Since then, she has served in key health leadership roles both internationally and domestically. As a Commander in the Commissioned Corps of the U.S. Public Health Service, assigned to CDC, she worked as a medical epidemiologist for the Division of HIV/AIDS Prevention, CDC Country Director and DGHA lead in Zimbabwe, and senior scientific advisor to the President’s Emergency Plan for AIDS Relief (PEPFAR) at the Office of Global AIDS Coordinator. In 2007, she left the Federal Government to work for the District of Columbia Department of Health, where she served as the director of the HIV/AIDS, Hepatitis, STD, and TB Administration for three years.

Dr. Hader comes to DGHA from Futures Group, where she served as Vice President and Director for the Center for Health Systems and Solutions. In addition to her work at Futures Group, Dr. Hader spent the past year as a Robert Wood Johnson Foundation Health Policy Fellow, where she served on the health policy staff of Senator Edward J. Markey of Massachusetts, chair of the Sub-committee on International Development and Foreign Assistance, Economic Affairs, International Environmental Protection, and Peace Corps, of the Senate Foreign Relations Committee.

Board-certified in Internal Medicine, Pediatrics, and Infectious Diseases, Dr. Hader earned her medical degree and master of public health from Columbia University and her BS in biological sciences from Stanford University. She completed a combined medicine/pediatrics residency at Duke University, and an infectious diseases fellowship at Emory University. She has served as a clinical assistant professor of medicine at Emory University, and was a Katherine Houghton Hepburn Fellow at Bryn Mawr College.

I would also like to take this opportunity to thank Dr. John Blandford for serving as Acting Director of DGHA since April 2014. John demonstrated exemplary leadership and made significant contributions to the Division while in his role as Acting Director, successfully guiding CDC’s response to strategic shifts in the PEPFAR program and playing a key role in shaping the Division’s human rights agenda. We are incredibly appreciative of John for his dedicated service to the Division.

Please join me in welcoming and supporting Dr. Hader in her new role at DGHA as well as thanking John for his outstanding leadership as the acting Division Director.

Kind regards,

Tom Kenyon MD MPH
Center for Global Health

Ebola funding shouldn’t come at the expense of other global health concerns

Posted on in Blog Posts, Infectious Disease, News Center

Cross-posted from The Washington Post by Dr. Christine Sow, Executive Director

The Obama administration’s announcement that the U.S. military will provide logistical support to stop the spread of the Ebola virus is a welcome indication that this interest is emerging as a priority [“U.S. military to help fight Ebola in Africa,” front page, Sept. 8]. The question is whether Congress takes it equally seriously.

Congressional Republicans have seemed reluctant to include supplemental funding requests in current budget negotiations, so the fate of the request for an additional $88 million is iffy at best. Instead, money already allocated for global health would fund the response, meaning less money for tuberculosis and malaria and depleted funds for health systems serving children and families in developing countries.

Redirecting funds would be a shortsighted strategy to respond to a rapidly growing crisis. The U.S. government must provide funding and leadership commensurate with the Ebola emergency while maintaining the country’s place as a global leader in the fight on child and maternal mortality and HIV/AIDS.

New single-size contraceptive diaphragm cleared for marketing in U.S.

Posted on in Women's Health


Women in the United States are a step closer to a new non-hormonal method of family planning that is effective, safe and reusable. The U.S. Agency for International Development (USAID) and partner organization, PATH, are pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared the Caya® contoured diaphragm for marketing in the United States.

The Caya® contoured diaphragm is a one-size-fits-most barrier method developed in collaboration between partner organizations, including PATH and CONRAD, with funding from USAID. The novel design makes the device easy to use by eliminating many of the challenges traditionally associated with diaphragms. Pelvic exams for sizing are not required, and clinics will not need to stock multiple sizes.

Widely considered the gold standard for stringent regulatory approval, the FDA’s regulatory review and clearance for the Caya® contoured diaphragm is an example of USAID’s investments abroad serving women in the United States for a truly global impact. In fact, as a result of USAID’s Expanding Effective Contraceptive Options project, women in Malawi and Zambia will soon be the first in the world to have this new contraceptive available to them. The device is approved in Malawi, and registration is in process in Zambia.

Learn more:

President Obama Pledges Additional Funding & Military Assistance to Combat Ebola

Posted on in Blog Posts, Global Health Budget

As the number of cases of Ebola continues to rise in West Africa, President Obama has pledged additional assistance from the United States.

President Obama has requested an additional $88 million ($30 million to CDC and $58 million to the Biological Advanced Research and Development Authority (BARDA)) to cover the cost of drugs, primarily the acceleration of the development and manufacturing of ZMapp and two vaccines, and personnel to help combat the deadly virus. Congress will need to approve the additional funding as part of a continuing resolution (CR) that will keep the government funded through mid-December (read more on the FY15 appropriations process on GHC’s blog). If approved, the additional funding will bring the total U.S. commitment to over $250 million.

Congress returned from August recess this week and it remains to be seen how they will respond to the funding request. Roll Call reported last week that Republican leaders would like to avoid adding additional funding provisions to the CR. With tight spending caps imposed on non-defense spending, the additional funding for Ebola could come at the expense of other funding priorities.

On Sunday, President Obama also announced that the U.S. military will provide assistance in West Africa. No details were given as to when and where the U.S. military will be deployed, but they are expected to provide equipment and other resources.

Photo Gallery: High level roundtable with the First Lady of the Republic of Mozambique

Posted on in Blog Posts, Maternal & Child Health, Media, News Center

The Global Health Council hosted a high level roundtable with the First Lady of the Republic of Mozambique, H.E. Mrs. Maria Da Luz Dai Guebuza on August 5, 2014 in Washington, D.C. GHC’s Executive Director, Dr. Christine Sow, and other global health partners attended the meeting which was held as a side event around the US-Africa Leaders Summit. View photos from the meeting here.

Mailing: Global Health Council, c/o Global Impact
1199 N. Fairfax Street, Suite 300, Alexandria, VA 22314
Physical: Global Health Council
1120 20th St. NW, Suite 500 N, Washington, DC 20036